Cargando…
The next controversy in genetic testing: clinical data as trade secrets?
Sole-source business models for genetic testing can create private databases containing information vital to interpreting the clinical significance of human genetic variations. But incomplete access to those databases threatens to impede the clinical interpretation of genomic medicine. National heal...
Autores principales: | Cook-Deegan, Robert, Conley, John M, Evans, James P, Vorhaus, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658186/ https://www.ncbi.nlm.nih.gov/pubmed/23150081 http://dx.doi.org/10.1038/ejhg.2012.217 |
Ejemplares similares
-
The Bell Curve Revisited: Testing Controversial Hypotheses with Molecular Genetic Data
por: Conley, Dalton, et al.
Publicado: (2016) -
Genetic testing for mitochondrial disease: the United Kingdom best practice guidelines
por: Mavraki, Eleni, et al.
Publicado: (2022) -
Recommendations for reporting results of diagnostic genetic testing (biochemical, cytogenetic and molecular genetic)
por: Claustres, Mireille, et al.
Publicado: (2014) -
EMQN best practice guidelines for genetic testing in dystrophinopathies
por: Fratter, Carl, et al.
Publicado: (2020) -
Guidelines for diagnostic next-generation sequencing
por: Matthijs, Gert, et al.
Publicado: (2016)